NCT06872541Active, not recruitingPhase 2/3
Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas
Source: ClinicalTrials.gov · Last updated 12 Mar 2025
Brief summary (registry, in English)
Cancer patients are at greater risk of experiencing events thrombotic, arterial or venous, during the course of the disease. Specifically in lung cancer, patients are seven times more prone to developing venous thrombosis, when compared to general population. Platelets influence cancer progression and Tumor microenvironment facilitates platelet activation. Therefore, the main objective of this project is to evaluate platelet aggregation analyzed by aggregometry optics with the use of AggRAM® equipment in patients diagnosed recent non-small cell lung carcinomas, prior to any oncological treatment. Among the secondary objectives, it stands out analyze the primary objective using the PPAnalysis® method (method in developed by our group in partnership with the University of Readings (UK), Plateletworks® and Chrono-log. This is a case-control study, with groups differentiated by the presence or absence of malignant lung neoplasia and matched by age, sex and presence or absence of smoking in the previous 6 months to inclusion. Patients diagnosed with non-cell lung carcinoma Small children without prior treatment will be candidates for participation in the study. It is expected that at the end important aspects related to aggregation platelet disease are better characterized in this neoplasm, the most important cause of death from cancer in the world, and therapeutic strategies to improvement in morbidity and mortality in the disease can be developed.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 6 Mar 2025
- Start date
- 20 Jan 2025
- Primary completion date
- 20 Oct 2026
- Lead sponsor
- University of Sao Paulo
- Diseases
- Lung cancer
- NCT number
- NCT06872541
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 100
- From 20 Jan 2025 to the primary completion date, 20 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of any non-steroidal anti-inflammatory drugs in the last 30 days;
Other illness
- Known coagulation disorder;
Lab values
- Known platelet dysfunction or platelets \<100,000/mm3 or \>450,000/mm3;
- Creatinine clearance by MDRD \<30 ml/min/1.73 m2
Other
- Anticoagulation in the last 30 days;
- Use of any antiplatelet agent in the last 30 days;
- Eastern Cooperative Oncology Group Performance Status Scale (ECOG) \>2
- Hematocrit less than 34% or greater than 55%
Who the study is looking for
- Patients \> 18 years old;
- Confirmed diagnosis of non-small cell lung carcinoma in the case group; absence of history of any neoplasia for control group
- Agreement to sign the Free and Informed Consent Form
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Heart Institute (InCor) / University of São Paulo Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.